retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Agonism Based Therapies for | Current Cardiovascular Risk Reports ADA 2026: Retatrutide Revolution

[DOI] [PMC free article] [PubMed] [Google Scholar] 579.Hvidberg A., Nielsen M.T., Hilsted J., Orskov C., Holst J.J

The primary outcome was the mean HbA1c change from baseline to 56 weeks, which was significantly reduced in both semaglutide groups against sitagliptin

GLP-1 works beautifullystimulating insulin, suppressing glucagon, and slowing gastric emptyingbut it has a fatal flaw: It is destroyed by the enzyme DPP-4 within minutes of entering the bloodstream

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids

Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world